TG Therapeutics raises funds for cancer combination drug

TG Therapeutics provided one of the highlights of the American Society of Hematology (ASH) conference earlier this month after lifting the lid on phase 3 data from its potential challenger

CLL patients in England to get AZ's Calquence after okay fro...

NHS England is to grant immediate access to AstraZeneca’s cancer drug Calquence (acalabrutinib) for certain patients with chronic lymphocytic leukaemia (CLL) after NICE backed it in first d

TG Therapeutics challenges Roche with FDA filing for CLL dru...

US biotech TG Therapeutics has begun a rolling filing with the FDA for its combination therapy for chronic lymphocytic leukaemia, in a challenge to Roche.

NICE backs chemo-free CLL combination from AbbVie and Roche

Previously untreated patients with chronic lymphocytic leukaemia (CLL) in England will get a chemotherapy-free treatment option after NICE recommended NHS funding for a combination of AbbVi

AbbVie, J&J embed Imbruvica deeper in CLL therapy with new a...

ASH19: AZ’s Calquence throws gauntlet down to Imbruvica